Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT ID: NCT01273779

Last Updated: 2012-02-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

1280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit

Talactoferrin alfa

Group Type EXPERIMENTAL

Talactoferrin alfa

Intervention Type DRUG

15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Talactoferrin alfa

15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit

Intervention Type DRUG

Placebo

15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than or equal to 18 years
* Onset of severe sepsis within the previous 24 hours
* Must be receiving antibiotic therapy
* Informed consent form signed by patient or authorized representatives according to local rules or regulations
* Able to take liquid medication by mouth or feeding tube

Exclusion Criteria

* Receipt of investigational medication within 4 weeks prior to participation in the study
* Pregnant or breast-feeding
* Severe congestive heart failure
* Known severe HIV infection
* Presence of severe burns
* Patients on high dose immunosuppressants
* Patients whose death is considered imminent
* Patients whose life expectancy for concurrent illness is less than 6 months
* Severe hypoxic encephalopathy or persistent vegetative state
* Severe liver disease
* Chronically bed bound
* Patient, legal representative or patient's primary physician not committed to providing full, aggressive life support
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Agennix

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama - Birmingham

Birmingham, Alabama, United States

Site Status

Providence Hospital

Mobile, Alabama, United States

Site Status

Maricopa Medical Center

Maricopa, Arizona, United States

Site Status

St. Joseph Hospital

Orange, California, United States

Site Status

Sharp Memorial Hospital

San Diego, California, United States

Site Status

Stanford University Hospital

Stanford, California, United States

Site Status

UCLA Medical Center

Sylmar, California, United States

Site Status

Denver Health Medical Center

Denver, Colorado, United States

Site Status

Christiana Care Health Services

Newark, Delaware, United States

Site Status

George Washington University Hospital

Washington D.C., District of Columbia, United States

Site Status

Bay Area Chest Physicians

Clearwater, Florida, United States

Site Status

Eastern Idaho Medical Consultants

Idaho Falls, Idaho, United States

Site Status

West Suburban Hospital Medical Center

Oak Park, Illinois, United States

Site Status

Peoria Pulmonary Associates

Peoria, Illinois, United States

Site Status

Methodist Research Institute

Indianapolis, Indiana, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Baystate Medical Center

Springfield, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

St. Johns Mercy Medical Center

St Louis, Missouri, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Cooper University Hospital

Camden, New Jersey, United States

Site Status

Moses Cone Memorial Hospital

Greensboro, North Carolina, United States

Site Status

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Site Status

Riverside Methodist Hospital

Columbus, Ohio, United States

Site Status

St. Vincent Mercy Medical Center

Toledo, Ohio, United States

Site Status

University of Oklahoma Health Science Center

Oklahoma City, Oklahoma, United States

Site Status

Cancer Institute, Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

University of Tennessee

Memphis, Tennessee, United States

Site Status

Texas Tech Health Science Center

El Paso, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

LDS Hospital

Murray, Utah, United States

Site Status

University of Wisconsin Medical School

Madison, Wisconsin, United States

Site Status

Clinique Saint-Pierre

Ottignies, Ottignies, Belgium

Site Status

Hôpitaux IRIS Sud

Brussels, , Belgium

Site Status

Hôpital Erasme

Brussels, , Belgium

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

CHU de Liège

Liège, , Belgium

Site Status

Centre Hospitalier de Dinant

Mons, , Belgium

Site Status

Cliniques Universitaires UCL de Mont-Godinne

Yvoir, , Belgium

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

Royal Jubilee Hospital

Victoria, British Columbia, Canada

Site Status

St. Boniface General Hospital

Winnipeg, Manitoba, Canada

Site Status

Health Sciences Centre

Winnipeg, Manitoba, Canada

Site Status

Grace Hospital

Winnipeg, Manitoba, Canada

Site Status

Queen Elizabeth II Health Sciences Center

Halifax, Nova Scotia, Canada

Site Status

Kingston General Hospital

Kingston, Ontario, Canada

Site Status

Windsor Regional Hospital

Windsor, Ontario, Canada

Site Status

SMBD - Jewish General Hospital

Montreal, Quebec, Canada

Site Status

Aalborg Sygehus

Aalborg, , Denmark

Site Status

Odense universitetshospital

Odense, , Denmark

Site Status

Hôpital Universitaire Dupuytren

Limoges, Limoges, France

Site Status

Hôtel Dieu

Angers, , France

Site Status

Centre Hospitalier Victor Dupouy

Argenteuil, , France

Site Status

Centre Hospitalier Départemental La Roche sur Yon, Luçon, Montaigu - Les Oudaries

La Roche-sur-Yon, , France

Site Status

Hôpital Albert Michallon / La Tronche

La Tronche, , France

Site Status

Centre Hospitalier de Montauban

Montauban, , France

Site Status

Hôpital de la Source

Orléans, , France

Site Status

Hôpital Cochin

Paris, , France

Site Status

Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status

Hôpital de la Miletrie

Poitiers, , France

Site Status

Centre Hospitalier Angouleme

Saint-Michel, , France

Site Status

Hôpital Bretonneau

Tours, , France

Site Status

Charité - Universitätsmedizin Berlin

Berlin, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Helios Klinikum Erfurt

Erfurt, , Germany

Site Status

Klinikum der Johann-Wolfgang Goethe-Universität

Frankfurt am Main, , Germany

Site Status

Klinikum der Friedrich-Schiller-Universität Jena

Jena, , Germany

Site Status

Klinikum der Stadt Ludwigshafen gGmbH

Ludwigshafen, , Germany

Site Status

Klinikum Harlaching

München, , Germany

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

The Lady Davis Carmel Medical Center

Haifa, , Israel

Site Status

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status

Hadassah University Hospital Ein Kerem

Jerusalem, , Israel

Site Status

Western Galilee Hospital - Nahariya

Nahariya, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, , Netherlands

Site Status

VU Medisch Centrum

Amsterdam, , Netherlands

Site Status

Gelre Ziekenhuizen

Apeldoorn, , Netherlands

Site Status

Medisch Centrum Leeuwarden

Leeuwarden, , Netherlands

Site Status

UMC St. Radboud

Nijmegen, , Netherlands

Site Status

Ikazia Ziekenhuis

Rotterdam, , Netherlands

Site Status

Hospital del Mar

Barcelona, Catalonia, Spain

Site Status

Hospital Universitari De Bellvitge

L'Hospitalet de Llobregat, Catalonia, Spain

Site Status

Hospital de Sabadell

Sabadell, Catalonia, Spain

Site Status

Hospital Universitari de Tarragona Joan XXIII

Tarragona, Catalonia, Spain

Site Status

Hospital Mutua de Terrassa

Terrassa, Catalonia, Spain

Site Status

Hospital Clinico San Carlos

Madrid, Madrid, Communidad de, Spain

Site Status

Hospital Universitario La Paz

Madrid, Madrid, Communidad de, Spain

Site Status

Hospital Universitario de Getafe

Getafe, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Site Status

St James's University Hospital

Leeds, , United Kingdom

Site Status

St John's Hospital

Livingston, , United Kingdom

Site Status

University College London

London, , United Kingdom

Site Status

St. Thomas' Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada Denmark France Germany Israel Netherlands Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Vincent JL, Marshall JC, Dellinger RP, Simonson SG, Guntupalli K, Levy MM, Singer M, Malik R; Oral tAlactoferrin in Severe sepsIS Study Investigators. Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial. Crit Care Med. 2015 Sep;43(9):1832-8. doi: 10.1097/CCM.0000000000001090.

Reference Type DERIVED
PMID: 26010687 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LF-0802

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Alpha-Lipoic Acid in Patients With Sepsis
NCT05808946 UNKNOWN PHASE2/PHASE3
The Efficacy and Safety of Ta1 for Sepsis
NCT02867267 COMPLETED PHASE3
The CRISIS Prevention Study
NCT00395161 TERMINATED PHASE3